Administrative Claims Analysis of the Relationship Between Warfarin Use and Risk of Hemorrhage Including Drug-Drug and Drug-Disease Interactions

KUI ZHANG, MD; CHRISTOPHER YOUNG, PhD; and JAN BERGER, MD

ABSTRACT

BACKGROUND: Despite the risk of hemorrhage, warfarin is the most commonly used oral anticoagulant today, both as monotherapy and when taken in combination with selected drugs. Warfarin is used most commonly for irregular heartbeat, after a heart attack, and after joint or heart valve replacement surgery.

OBJECTIVE: To evaluate the relative risk of hemorrhage in health plan members who received warfarin concomitant with a drug known to cause an interaction or after diagnosis of liver disease or heart failure (HF).

METHODS: A cohort study sample was drawn from an administrative database comprising medical and pharmacy claims for 1.7 million health plan members. A health plan member was defined as anyone who was eligible for pharmacy and medical benefits at any time from October 1, 2003, to September 30, 2004. To be included in the study, a member must have received at least 1 pharmacy claim for warfarin during the study period and been younger than 100 years.

Hemorrhage was defined as a diagnosed bleeding episode recorded on a medical claim within 7 calendar days of a fill date for a pharmacy claim (new or refill) for warfarin. The following variables were used to predict the outcome measures: type of drug-drug or drug-disease interaction, patient age and gender, number of unique prescribers during the year for all drugs, specialty of the first prescriber for warfarin, average dose of warfarin, and days of warfarin therapy. Because individuals were followed only during the calendar year under study, the authors have interpreted the days of therapy measured primarily as a control on exposure. The outcome measures are prevalence of drug and disease interactions among members receiving warfarin therapy and the per-patient-per-year and per-member-per-month (PMPM) cost of medical treatment of hemorrhage associated with warfarin therapy including drug and disease interactions. Costs are defined as the total paid amount for a procedure or service after negotiated provider discounts and subtraction of patient copay and deductibles. Logistic regression was used to evaluate the relative risk of hemorrhage in users of warfarin monotherapy and of warfarin users with drug-drug and drug-disease interactions. The comparison group in the logistic regression comprised the members who were not diagnosed with either HF or liver disease and who received warfarin therapy but none of the drugs under study known to cause drug interactions. Therefore, the odds ratios (ORs) produced were estimates of the relative risk of hemorrhage when taking warfarin concomitant with selected drugs and diseases.

RESULTS: Of the 17,895 patients who used warfarin during the study year, 2,634 (14.7%) were diagnosed with a hemorrhage event within 1 week after filling a prescription for warfarin. The factors associated with an increased risk of hemorrhage included female gender (OR 1.149; 95% confidence interval [CI], 1.053-1.253), liver disease (OR 1.764; 95% CI, 1.360-2.288), and HF (OR 1.559; 95% CI, 1.373-1.770). Compared with the use of warfarin alone, the use of either cephalosporins (OR 1.157; 95% CI, 1.043-1.285) or metronidazole (OR 1.578; 95% CI, 1.321-1.868) was associated with increased risk of hemorrhage, whereas the risk of hemorrhage was not greater for concomitant use of warfarin with amiodarone, fibrin acid derivatives, or nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors. There was no relationship between estimated average daily warfarin dose and prevalence of hemorrhage.

Other variables associated with an increased risk of hemorrhage were increased patient age, female gender, 120 days or more of warfarin therapy during the year, 2 or more unique prescriber numbers, and the medical specialty of the first prescriber of warfarin. Over the population of 1.7 million members, the cost for all hemorrhage events within 7 days of a pharmacy claim for warfarin was $0.40 PMPM.

CONCLUSIONS: Only 2 of 5 combinations of warfarin with drugs in this study were found to be associated with a higher prevalence of hemorrhage compared with warfarin use alone. The absolute prevalence of hemorrhage in users of warfarin and metronidazole was 22.7% and 17.2% for warfarin and cephalosporins, respectively, versus 14.2% in users of warfarin alone. The prevalence of hemorrhage for concomitant use of warfarin and NSAIDs/COX-2 inhibitors, amiodarone, or fibrin acid derivatives such as fenofibrate was not greater than for warfarin alone. Liver disease or HF in warfarin users was associated with a significant increase in the likelihood of hemorrhage.

KEYWORDS: Patient safety, Warfarin

J Manag Care Pharm. 2006;12(8):640-48

Note: An editorial on the subject of this article appears on pages 686-87 of this issue.

Authors

KUI ZHANG, MD, is a manager and CHRISTOPHER YOUNG, PhD, is a director, Department of Research and Development, and JAN BERGER, MD, is chief clinical officer, CaremarkRx, Hunt Valley, Maryland.

AUTHOR CORRESPONDENCE: Kui Zhang, MD, Manager, Department of Research and Development, CaremarkRx, 11311 McCormick Rd., Hunt Valley, MD 21031. Tel: (410) 785-3349; Fax: (410) 785-8140; E-mail: kui.zhang@caremark.com

Copyright© 2006, Academy of Managed Care Pharmacy. All rights reserved.
Hemorrhage is a concern for warfarin monotherapy and for warfarin used concomitantly with other drugs and in the presence of certain diseases. Of particular concern are warfarin users with heart failure (HF) who subsequently suffer from hepatic dysfunction and are at increased risk of hemorrhage. Gurwitz et al. found that hemorrhage is the most common type of preventable adverse drug event among older persons in an ambulatory clinical setting. Landefeld and Beyth found that the average annual frequencies of fatal, major, and major or minor bleeding during warfarin therapy were 0.6%, 3.0%, and 9.6%, respectively. These frequencies are approximately 5 times those expected without warfarin therapy. Individuals who use warfarin either concomitantly with certain drugs, such as mifepristone, antiplatelet medications, aspirin, certain fibric acid derivatives, or metronidazole, or who are diagnosed with certain conditions, including liver disease, active bleeding, recent trauma, or blood dyscrasias, are at increased risk of hemorrhage.

While the potential dangers of warfarin drug-drug and drug-disease interactions and the prevalence of concomitant use of warfarin with drugs that may result in a drug-drug and drug-disease interaction are known, less is known about the prevalence of clinical consequences and the cost of these drug-drug and drug-disease interactions. Evidence of clinical and economic consequences of drug-drug and drug-disease interactions may help quantify the need for additional education and/or other interventions. In this study, we used administrative medical and pharmacy claims data to evaluate the relative risk of hemorrhage in individuals taking warfarin concomitantly with other drug therapy known to be associated with drug interactions or with diagnosed liver disease, compared with the use of warfarin alone. The working hypothesis of this study is that patients using warfarin concomitantly with selected drugs and diseases (see Methods) have a greater relative risk of hemorrhage than do patients taking warfarin alone.

**Methods**

This analysis was conducted from the perspectives of the health plan and payer to provide information on the incidence of drug-drug and drug-disease interactions and of related adverse events. In this way, the information created in this study focuses not on the member’s risk of hemorrhage but on the overall clinical and economic costs that a health plan payer bears as a consequence of drug-drug and drug-disease interaction. Benefits eligibility, which ensures that all information for a study subject is available for examination, does not allow for estimates of overall incidence of drug-drug and drug-disease interactions in a population. In an eligibility-controlled analysis, members without a full year of eligibility because of death or termination of benefits or for some other reason would be dropped from the analysis.

Therefore, rather than conducting a retrospective longitudinal analysis of individuals, tracking their use of medications after their first diagnosis of hemorrhage, we chose to analyze 1 calendar year of administrative claims data. This cohort study sample of combined deidentified medical and pharmacy claims data was drawn from 1.7 million health plan members for whom both medical and prescription data were available to Caremark Rx, a pharmacy benefits manager (PBM). This PBM provides services to a subset of these plans that require the health plans to provide medical claims data. The database of pharmacy and medical claims represented approximately 1.7 million individuals who were eligible for pharmacy and medical benefits at some time during the period under study (October 1, 2003, to September 30, 2004). To be included in the study, an individual must have been a member of a health plan that provided both medical and pharmacy claims data, must have received at least 1 pharmacy claim for warfarin during the study period, and must have been younger than 100 years. Table 1 describes the selection of the final study sample of 17,895 members who used warfarin during the year.

We followed 3 sets of events over time in this analysis: (1) the receipt of 2 pharmaceuticals or a pharmaceutical and a diagnosis that might result in a drug-drug or drug-disease interaction, (2) the diagnosis of hemorrhage within 1 week after the drug-drug or drug-disease interaction, and (3) the paid (plan) costs of hemorrhage that occurred after the drug-drug or drug-disease interaction through the end of the calendar year. Detailed definitions and descriptions of the selection process for drugs and diseases under study and of each of these outcomes follow below.

The primary source we used to identify potential warfarin-drug and warfarin-disease interactions was the book Pharmacology. From this volume, we obtained a list of warfarin interactions from the section on warfarin (pp. 321, 322). To supplement this source, we used computer searches of medscape.com and google.com of the phrase “interactions of warfarin with drugs.” From this list, we considered for study drugs that potentiate the anticoagulant effect of warfarin and that have one of the following characteristics: (1) inhibit hepatic drug metabolism (cimetidine, imipramine, co-trimoxazole, chloramphenicol, ciprofloxacin, metronidazole, and amiodarone);
(2) inhibit platelet function (nonsteroidal anti-inflammatory drugs [NSAIDs], moxalactam, carbencillin, and aspirin); (3) displace warfarin from binding sites on plasma albumin (some NSAIDs and chloral hydrate); (4) inhibit production of vitamin K (oral cephalosporins); (5) decrease the availability of vitamin K (sulfonamides); or (6) induce hepatic P450 enzymes (barbiturates, carbamazepine, griseofulvin, and rifampin). All these drugs will increase the degradation of warfarin. Heparin, which is an injectable anticoagulant, was considered for our study. Using this method, the authors endeavored to define a complete list of potential warfarin drug-drug and drug-disease interactions for study.

From those classes of drugs, we selected the following drugs and drug classes for study for which we had a pharmacy claim: NSAIDs, barbiturates, heparin, cimetidine, ciprofloxacin, metronidazole, carbamazepine, imipramine, amiodarone, cephalosporins, chloramphenicol, griseofulvin, rifampin, moxalactam, and carbencillin. Of those drugs, the following had a prevalence of less than 1% and were too rare to be evaluated with traditional statistical methods: chloramphenicol, griseofulvin, rifampin, moxalactam, carbencillin, barbiturates, heparin, cimetidine, ciprofloxacin, carbamazepine, and imipramine. Of these, carbamazepine had the greatest count of members, with 117 utilizers. Again, because concomitant use of 2 drugs with a potential drug-drug and drug-disease interaction concomitant with warfarin was uncommon, statistical evaluation was not possible for multiple, potentially interacting drugs.

We considered 3 medical conditions for analysis: liver disease, HF, and thyrotoxicosis. Of those conditions, HF and liver disease occurred often enough in the study population to allow the use of statistical methods to evaluate the risk of hemorrhage.

Using these clinical and empirical criteria, warfarin users with a potential drug-drug and drug-disease interaction were identified and grouped for study using the following criteria: a diagnosis of liver disease (International Classification of Diseases, Ninth Revision, Clinical Modification, [ICD-9-CM] of 570.xx, 571.xx, 572.xx, or 573.xx) or HF (ICD-9-CM) of 428.0, 428.22, 428.23, 428.32, 428.33, 428.34, 428.42, or 428.43) or who received a pharmacy claim for one of the following drugs or drug classes: NSAIDs (including cyclooxygenase-2 [COX-2] inhibitors), metronidazole, amiodarone, cephalosporins, and fibrin acid derivatives.

A member with a potential drug-drug interaction was defined as an individual who had pharmacy claims in the database for 1 of these drugs and warfarin with at least 1 day of overlap in days supply of the 2 drugs. Members were not differentiated on the basis of the number of days of overlap. A member with a potential drug-disease interaction was defined as a member recently diagnosed with liver disease or HF. The criterion was selected arbitrarily as the presence of a diagnosis code within 3 weeks before a member filled a warfarin pharmacy claim. Hemorrhage was defined as the presence of a diagnosis code (Table 2) on a medical or hospital claim for a member who received a warfarin fill in the previous 7 calendar days. As noted in the footnote to Table 3, individuals who received warfarin through mail order would have a smaller number of “windows” during which we would count hemorrhaging. Following a conservative approach to estimation, we have not attempted to account for this difference by adding days to mail-order claims. Therefore, the cohort was defined as the group of individuals with a potential drug-drug and drug-disease interaction who, within 7 calendar days, experienced hemorrhage. This episode of hemorrhage was assumed to be related to the drug-drug and drug-disease interaction.

We evaluated the rate of hemorrhage in a comparison group of individuals who received warfarin therapy but no interacting pharmaceutical therapy or medical condition. The relative risk of hemorrhage was evaluated by comparing the rate of hemorrhage in those cohorts to the rate of hemorrhage in members who used only warfarin and who were not diagnosed with either liver disease or HF.

Direct medical costs were estimated using the total amount paid for a procedure or service after negotiated provider discounts and subtraction of patient copayment and deductibles for all records with a diagnosis of hemorrhage subsequent to the first instance of a drug-drug and drug-disease interaction. Included in these costs are inpatient hospital stays, outpatient hospital visits, emergency room visits, and lab tests. We did not
Univariate statistics were used to test as every patient. For the last prescription during the year, if the fill date for pharmacy claims from October 1, 2003, to September 30, 2004.

The comparison group in the logistic regression comprised the members who received warfarin therapy but no other drug therapy. Therefore, the odds ratios (ORs) produced were estimates of the relative risk of hemorrhage when taking warfarin concomitantly with other drugs. Logistic regression was used to evaluate the relative risk of hemorrhage in users of warfarin monotherapy and of warfarin users with other drug therapy. Bivariate relationships were evaluated with either chi-square or t tests as appropriate. Logistic regression was used to evaluate the relative risk of hemorrhage in users of warfarin monotherapy and of warfarin users with drug-drug and drug-disease interactions. The comparison group in the logistic regression comprised the members who received warfarin therapy but no other drug therapy. Therefore, the odds ratios (ORs) produced were estimates of the relative risk of hemorrhage when taking warfarin concomitantly with selected drugs and diseases.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Study Sample (No.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age and gender</td>
<td>Age in years, mean [SD]</td>
</tr>
<tr>
<td>Warfarin dose and length of therapy</td>
<td>Warfarin dose in mg†, mean [SD]</td>
</tr>
<tr>
<td>Less than 120 days of warfarin therapy, n (%)</td>
<td>7,209 (40.3)</td>
</tr>
<tr>
<td>121-180 days of warfarin therapy, n (%)</td>
<td>2,518 (14.1)</td>
</tr>
<tr>
<td>181+ days of warfarin therapy, n (%)</td>
<td>8,168 (45.7)</td>
</tr>
<tr>
<td>Prescriber numbers and medical specialty</td>
<td>Prescriber numbers, mean [SD]</td>
</tr>
<tr>
<td>Unique prescriber numbers</td>
<td>9,305 (52.0)</td>
</tr>
<tr>
<td>Primary practitioner, n (%)</td>
<td>3,564 (19.9)</td>
</tr>
<tr>
<td>Cardiovascular specialty, n (%)</td>
<td>2,245 (12.6)</td>
</tr>
<tr>
<td>Other specialty, n (%)</td>
<td>2,781 (15.5)</td>
</tr>
<tr>
<td>Medical diagnoses for hemorrhage or heart failure</td>
<td>Medical diagnoses for hemorrhage or heart failure</td>
</tr>
<tr>
<td>Heart failure, n (%)</td>
<td>1,875 (10.5)</td>
</tr>
<tr>
<td>Liver disease, n (%)</td>
<td>315 (1.8)</td>
</tr>
<tr>
<td>Most frequent hemorrhage diagnosis codes, n (%)</td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic disorder due to circulating anticoagulants (ICD-9-CM=286.5)</td>
<td>640 (2.6)</td>
</tr>
<tr>
<td>Hemorrhage of gastrointestinal tract, unspecified (ICD-9-CM=578.9)</td>
<td>295 (1.7)</td>
</tr>
<tr>
<td>Hemorrhage of rectum and anus (ICD-9-CM=569.3)</td>
<td>223 (1.3)</td>
</tr>
<tr>
<td>Hemorrhage from nose, nasoceleb (ICD-9-CM=784.7)</td>
<td>151 (0.8)</td>
</tr>
<tr>
<td>Hemothysitis (cough with hemorrhage; pulmonary hemorrhage NO5, ICD-9-CM=786.3)</td>
<td>93 (0.5)</td>
</tr>
</tbody>
</table>

* Fill date for pharmacy claims from October 1, 2003, to September 30, 2004.
† The distribution of warfarin pharmacy claims by strength: 12,710 (11.9%) 1 mg, 11,537 (10.8%) 2 mg, 8,649 (8.1%) 2.5 mg, 6,671 (6.3%) 3 mg, 8,993 (8.4%) 4 mg, 47,290 (44.3%) 5 mg, 3,276 (3.1%) 6 mg, 4,037 (3.8%) 7.5 mg, 3,514 (3.2%) 10 mg.
‡ Hemorrhage was defined by more than 100 ICD-9-CM codes (see Table 2).
Mail-order prescriptions for a larger days supply of warfarin, typically 90 days, would result in a reduction in the opportunity to pair the hemorrhage diagnosis in the 7-day period; i.e., mail-order warfarin claims may result in an underestimate of the number of bleeding episodes associated with warfarin use as defined by the criteria in the present study. ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification; NOS=not otherwise specified.
Administrative Claims Analysis of the Relationship Between Warfarin Use and Risk of Hemorrhage Including Drug-Drug and Drug-Disease Interactions

Results

Of the 1.7 million members eligible for drug and medical benefits during the study period (see below), 17,895 members filled at least 1 pharmacy claim for warfarin and were selected for study (Table 3). Warfarin users averaged age 64.3 years with a standard deviation of 14.6 years. The study patients received prescriptions from an average of 4.2 unique DEA numbers, although most warfarin users (73%) received all of their prescriptions from 5 or fewer prescribers.

Of the 17,895 members who used warfarin during the study year, 2,634 (14.7%) were diagnosed with hemorrhage subsequent to filling a prescription for warfarin. The most common hemorrhage diagnoses by ICD-9-CM code were hemorrhagic disorder due to circulating anticoagulants (286.5), hemorrhage of gastrointestinal tract, unspecified (578.9) hemorrhage of rectum and anus (569.3), hemorrhage from nose, nosebleed (784.7), hemoptysis (cough with hemorrhage) and pulmonary hemorrhage not otherwise specified (786.3) (Table 3). Of the warfarin users, 1,260 (7.0%) concomitantly received prescriptions for amiodarone, 4,906 (27.4%) for an NSAID/COX-2, 3,385 (18.9%) for cephalosporin, 779 (4.4%) for metronidazole, and 761 (4.3%) for fibric acid derivative. Of the NSAID/COX-2 drug-drug or drug-disease interactions, 3,114 (63.5%) were associated with a COX-2 inhibitor, 1,340 (26.6%) with a nonselective NSAID, and 452 (9.2%) with both. Of warfarin users, 315 (1.8%) had a diagnosis of liver disease and 1,875 (10.5%) had a diagnosis of HF. Table 4 reports the average age and gender for each drug-drug or drug-disease interaction pair.

The prevalence of hemorrhage, defined as a binary variable, was regressed on indicators for each of these drug-drug or drug-disease interactions as well as member age, gender, average warfarin dose, number of days of warfarin therapy, number of unique prescribers, a diagnosis of HF, and physician specialty of the first prescriber of warfarin during the study year. The result of logistic regression is presented in Table 5. Liver disease in warfarin users was associated with a significant increase in the likelihood of hemorrhage when compared with warfarin monotherapy users ($P<0.05$). Patients who were taking warfarin and who had a diagnosis of HF were 1.559 times as likely to be diagnosed subsequently with hemorrhage. Warfarin used concomitant with cephalosporins or metronidazole also was associated with significantly increased likelihood of hemorrhage over warfarin use alone ($P<0.05$). Members who received prescriptions from multiple prescribers were at higher risk of hemorrhage ($P<0.05$). Compared with patients who had their first prescription for warfarin written by a cardiologist, patients who received their first prescription for warfarin from any other specialist were associated with a higher risk of hemorrhage ($P<0.05$). Women were somewhat more likely to hemorrhage than men ($P<0.05$), and younger members were somewhat more likely to be diagnosed with hemorrhage ($P<0.05$). The risk of hemorrhage increased with the duration of warfarin use in days. The average daily dose of warfarin and concomitant use of amiodarone and fibric acid derivatives were not significantly related to the hemorrhage rate. NSAID/COX-2 use was negatively related to the likelihood of hemorrhage, although marginally so.

Overall, a cost of $0.40 PMPM was associated with hemorrhage events recorded in medical or hospital claims within 7 days of receipt of a warfarin fill. When disaggregated by the associated drug-drug or drug-disease interaction, the PMPM cost varied considerably according to the volume of the patients with each interaction. The PMPM cost associated with hemorrhage was $0.40 PMPM.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Prevalence of Hemorrhage* in Warfarin Users</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td>Patients</td>
</tr>
<tr>
<td>Warfarin-liver disease</td>
<td>315</td>
</tr>
<tr>
<td>Warfarin-metronidazole</td>
<td>779</td>
</tr>
<tr>
<td>Warfarin-cephalosporins</td>
<td>3,385</td>
</tr>
<tr>
<td>Warfarin-amiodarone</td>
<td>1,260</td>
</tr>
<tr>
<td>Warfarin-heart failure</td>
<td>1,875</td>
</tr>
<tr>
<td>Warfarin-NSAIDs</td>
<td>4,906</td>
</tr>
<tr>
<td>Warfarin only</td>
<td>9,147</td>
</tr>
<tr>
<td>Warfarin-fibric acid derivatives</td>
<td>761</td>
</tr>
<tr>
<td>Total</td>
<td>17,895</td>
</tr>
</tbody>
</table>

Note: Some members had more than 1 drug-drug or drug-disease interaction; therefore, the number of potential drug-drug or drug-disease interactions exceeds the reported total.

* Hemorrhage was defined from the presence of at least 1 of more than 100 ICD-9-CM codes (see Table 2).

ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; NSAIDs = nonsteroidal anti-inflammatory drugs.
Discussion

Over the last several years, there has been increasing focus on avoidable medical errors, especially avoidable medication errors. Although warfarin is a drug that has been on the market for many years and has significant use in the medical community, it remains a drug that can put a patient at risk for an adverse drug event.

Of the warfarin drug and disease interactions in the study, concomitant use of 5 drug categories occurred with a sufficient statistical frequency to evaluate the risk of hemorrhage. In addition, we evaluated comorbid heart disease and liver disease. Of the 5 drug categories, cephalosporins and metronidazole increased the likelihood of hemorrhage. Both cephalosporins and metronidazole are antibiotics, suggesting short-term use. Cephalosporins and metronidazole both have a relatively high incidence of use with warfarin and are associated with an increase in the likelihood of hemorrhage. This would suggest that greater care must be taken by clinicians who dispense these medications. Increased member-physician communication and education as well as programs such as pharmacy messaging, academic detailing of physicians by pharmacists, and electronic education as well as programs such as pharmacy messaging, can help prevent this type of drug-drug or drug-disease interaction.

In contrast, despite the high costs associated with warfarin-NSAID/COX-2 drug-drug or drug-disease interactions, these drug-drug or drug-disease interactions were negatively related to the likelihood of hemorrhage, although marginally so, as stated above. In part, this may be because many NSAIDs are now available over the counter, resulting in underreporting of the use of NSAIDs and therefore of warfarin-NSAID/COX-2 drug-drug or drug-disease interactions.

Members with liver disease also faced an increased likelihood of hemorrhage. Similarly, members with HF were more likely to also be diagnosed with hemorrhage. Because it appears that some members with HF have an increased responsiveness to oral anticoagulants, and because HF-induced hepatic congestion can cause hepatic dysfunction, practitioners may be faced with a patient who is being treated with warfarin and who has liver disease. The results of this study suggest that care must be taken when treating members with these 2 health problems.

The number of days of warfarin therapy was found to be positively related to the likelihood of hemorrhage. This study does not allow us to evaluate the reasons behind this finding. As noted in the Methods section, this variable may be, in part, a proxy for eligibility. It is possible that a member with longer-term warfarin therapy simply has more opportunities for drug-drug or drug-disease interactions that may result in adverse side effects. Further potential explanations for this may be that long-

### Table 5: Risk of Hemorrhage Among Warfarin Users*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds Ratio†</th>
<th>0.05 Wald Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female vs. male</strong></td>
<td>1.149†</td>
<td>1.053</td>
</tr>
<tr>
<td><strong>Decrease in age of 1 year</strong></td>
<td>1.099†</td>
<td>1.006</td>
</tr>
<tr>
<td><strong>Heart failure</strong></td>
<td>1.559†</td>
<td>1.373</td>
</tr>
<tr>
<td><strong>Liver disease</strong></td>
<td>1.764†</td>
<td>1.360</td>
</tr>
<tr>
<td><strong>Cephalosporins</strong></td>
<td>1.157†</td>
<td>1.043</td>
</tr>
<tr>
<td><strong>Metronidazole</strong></td>
<td>1.578†</td>
<td>1.321</td>
</tr>
<tr>
<td><strong>Amiodarone</strong></td>
<td>0.980</td>
<td>0.827</td>
</tr>
<tr>
<td><strong>Fibric acid derivatives</strong></td>
<td>0.823</td>
<td>0.660</td>
</tr>
<tr>
<td><strong>NSAIDs/COX-2s</strong></td>
<td>0.904†</td>
<td>0.820</td>
</tr>
<tr>
<td><strong>Average dose of warfarin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 mg</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>5 mg to 7.5 mg</td>
<td>1.077</td>
<td>0.966</td>
</tr>
<tr>
<td>More than 7.5 mg</td>
<td>1.071</td>
<td>0.962</td>
</tr>
<tr>
<td><strong>Days of warfarin therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤120 days</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>120 to 180 days</td>
<td>1.571†</td>
<td>1.373</td>
</tr>
<tr>
<td>More than 180 days</td>
<td>1.953†</td>
<td>1.771</td>
</tr>
<tr>
<td><strong>Number of unique prescriber numbers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>2-3</td>
<td>1.284†</td>
<td>1.082</td>
</tr>
<tr>
<td>≥4</td>
<td>1.799†</td>
<td>1.519</td>
</tr>
<tr>
<td><strong>Prescriber specialty</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Primary care practitioner</td>
<td>1.216†</td>
<td>1.097</td>
</tr>
<tr>
<td>Other specialty</td>
<td>1.303†</td>
<td>1.117</td>
</tr>
<tr>
<td><strong>Likelihood ratio = 441.29, 17 df, P ≤0.001.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Regression analysis.
† Odds ratios are significant at P ≤0.05.
‡ The medical specialty of the first prescriber of warfarin therapy.
COX-2 = cyclooxygenase-2; NSAIDs = nonsteroidal anti-inflammatory drugs.
term use itself may be related to hemorrhage, or it may take
longer for symptoms of some of the adverse events to become
acute enough to warrant a visit to a physician. This finding sug-
stests physicians’ review of chronic warfarin use may help pre-
vent adverse reactions. Warfarin use requires long-term moni-
toring. Members may not comply with testing, which may in-
crease the frequency of hemorrhage.

Tools such as prospective drug utilization reviews (pDURs)
were recently evaluated by Malone et al. with a nonrandom
sample of 46 million Americans. In this study, they found that
the pDUR employed by the PBM in the current study rejected
between 19% and 46% of claims that may result in a drug-drug
interaction, depending on the class of drugs.

On one hand, other tools such as prospective drug utiliza-
tion reviews (pDURs) that PBMs provide to pharmacies, may
help to reduce drug-drug interactions. Other tools such as
electronic prescribing and direct consultations with physicians
should be used to reinforce contraindications and risks of drug-
drug or drug-disease interactions when prescribing warfarin.

The risk associated with the use of warfarin necessitates
greater attention by physicians when initiating therapy and on
an ongoing basis. Even with this increased focus by physicians,
the risk of drug-drug or drug-disease interactions still exists
because of the fragmentation found in health care delivery today.

Due to the lack of transparency of care across all caregivers,
organizations such as PBMs and managed care organizations
will also have a role in this process. These organizations, by
virtue of their aggregation of all claims associated with a patient,
may not comply with testing, which may increase the frequency of hemorrhage.

Tools such as prospective drug utilization reviews (pDURs)
were recently evaluated by Malone et al. with a nonrandom
sample of 46 million Americans. In this study, they found that
the pDUR employed by the PBM in the current study rejected
between 19% and 46% of claims that may result in a drug-drug
interaction, depending on the class of drugs. On one hand,
these rates testify to the success of the pDUR program. On the
other, many drugs with the potential for drug-drug interactions
are prescribed despite the warnings. In their discussion of why
these drug-drug interactions continue to occur, Malone et al.
identified 1 factor as lack of physician awareness of drug-drug
interactions. They cited a survey of physicians in the Southern
California Veterans Affairs Healthcare System as properly iden-
tifying only 44% of drug-drug interactions as well as further
evidence that physicians and pharmacists did not recognize
many drug-drug interactions.

Compounding the problem of physician awareness may be
the number of different practitioners who prescribe drugs for
patients and the dispersion of medical and pharmacy records.
We found that the likelihood of hemorrhage is greater for
patients receiving prescriptions from a greater number of
prescriber numbers. This suggests that programs to increase
communication between practitioners also may help reduce
adverse reactions to drug-drug interactions. The results obtained
in this study, in which 2 out of 5 possible drug-drug interactions
were associated with a statistically significant increased risk of
hemorrhage compared with warfarin use alone, suggest that
further research is needed to identify which of the many possible
drug-drug interactions require focus for communication inter-
ventions with prescribers. Programs that give providers
information on the complete prescription history of their
patients, similar to the point-of-service (POS) drug utilization
review (DUR) services that PBMs provide to pharmacies, may
help to reduce drug-drug interactions.

Other tools such as electronic prescribing and direct consultations with physicians
should be used to reinforce contraindications and risks of drug-
drug or drug-disease interactions when prescribing warfarin.

Disease management programs focusing on HF should be
engaged in monitoring appropriate warfarin prescribing.

The risk associated with the use of warfarin necessitates
greater attention by physicians when initiating therapy and on
an ongoing basis. Even with this increased focus by physicians,
the risk of drug-drug or drug-disease interactions still exists
because of the fragmentation found in health care delivery today.

Due to the lack of transparency of care across all caregivers,
organizations such as PBMs and managed care organizations
will also have a role in this process. These organizations, by
virtue of their aggregation of all claims associated with a patient,
need to work with physicians to get them all the information
necessary to make a clinically informed prescribing decision.
This can be done through safety checks for all community or
mail-service pharmacy prescriptions with feedback to the pre-
scribing physician and through support of electronic prescribing.

The costs associated with drug-drug or drug-disease interac-
tions seem to warrant attention. When calculated per member
and per drug-drug or drug-disease interaction, costs associated
with drug-drug or drug-disease interactions suggest that,
in addition to reducing the risk of hemorrhage and further
complications, a program to reduce drug-drug or drug-disease
interactions could result in significant plan savings as well.
Many drug-drug or drug-disease interactions are approved by
physicians or pharmacists despite POS DUR alerts that notify
pharmacists of potential drug-drug or drug-disease interactions
at the time of claim adjudication.

Limitations
One of the primary limitations of this study is that data on the
international normalized ratio (INR) are not available. These
data on the INR would allow researchers to better evaluate
whether the anticoagulant therapy for these patients was within
therapeutic range. Another limitation is that the combination of
the large number of potential warfarin-drug interactions com-

### Table 6

<table>
<thead>
<tr>
<th>Drug</th>
<th>Patients</th>
<th>Total Cost ($)</th>
<th>PMPM ($)</th>
<th>PPPY ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin-NSAIDs/COX-2s</td>
<td>4,906</td>
<td>3,348,186</td>
<td>0.16</td>
<td>682</td>
</tr>
<tr>
<td>Warfarin only</td>
<td>9,147</td>
<td>2,679,841</td>
<td>0.13</td>
<td>293</td>
</tr>
<tr>
<td>Warfarin-cephalosporins</td>
<td>3,385</td>
<td>1,927,007</td>
<td>0.09</td>
<td>569</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1,875</td>
<td>1,242,693</td>
<td>0.06</td>
<td>663</td>
</tr>
<tr>
<td>Warfarin-fibrin acid derivatives</td>
<td>761</td>
<td>1,041,948</td>
<td>0.05</td>
<td>1,369</td>
</tr>
<tr>
<td>Warfarin-metronidazole</td>
<td>779</td>
<td>697,671</td>
<td>0.03</td>
<td>896</td>
</tr>
<tr>
<td>Warfarin-amiodarone</td>
<td>1,260</td>
<td>560,132</td>
<td>0.03</td>
<td>445</td>
</tr>
<tr>
<td>Warfarin-liver disease</td>
<td>315</td>
<td>357,368</td>
<td>0.02</td>
<td>1,135</td>
</tr>
<tr>
<td>Total</td>
<td>17,895</td>
<td>8,191,464</td>
<td>0.40</td>
<td>458</td>
</tr>
</tbody>
</table>

Note: Claims with dates of service from October 1, 2003, through September 30, 2004.

* Plan cost for all medical and hospital claims with a hemorrhage diagnosis
(see Table 2 for a list of the codes) within 7 days of a pharmacy claim for
warfarin. Some patients are represented in more than 1 row in the table,
causing the sum of the rows to exceed the reported total cost.
† PMPM is cost per member per month for approximately 1.7 million members.
‡ PPPY is cost per patient per year for the specific drug-drug or drug disease
interaction in this row of the table.

COX-2=cyclooxygenase-2; NSAIDs=nonsteroidal anti-inflammatory drugs.
combined with the limited size of the dataset made it impossible to evaluate the impact of all potential warfarin drug interactions. Yet another limitation is that we did not control for disease severity in this study.

Perhaps foremost in this study, the relationship between warfarin use and hemorrhage events is merely a temporal one, and it is not possible to attribute directly the hemorrhage claims to the use of warfarin alone or in combination with disease or drugs known to interact with warfarin. It is also possible that the costs attributed to hemorrhage events are overstated since claims aggregation was based on having a hemorrhage diagnosis on any field on the medical or hospital claim, not necessarily being the primary diagnosis on the claim.

We could not control for the use of over-the-counter products, herbal products (e.g., garlic, ginkgo biloba), or food consumed by the study subjects that is known to interact with warfarin. The lack of data on over-the-counter drugs may have had an impact on the results for the relative risk of hemorrhage in patients who received both warfarin and prescription NSAID/COX-2 therapy. Several natural products contain substances that have coumarin, salicylate, or antiplatelet properties. A theoretical risk for potentiation of the pharmacologic activity of warfarin exists, therefore, when these herbs or food are taken with warfarin. In addition, we did not distinguish hemorrhage by organ.

Another limitation is that the identification of drugs dispensed to inpatients is not available from administrative claims. Another consideration in the interpretation of these results is that only those bleeding events that resulted in visits to physicians or hospitals and were diagnosed as hemorrhages were considered in this analysis. Therefore, the nonsignificant results for some of the drug-drug or drug-disease interactions may mask problems that were not detected by physicians, not diagnosed, or not recorded as such. Further, the small incidence of some of the drug-drug or drug-disease interactions limited our ability to distinguish outcomes for many of the drug-drug or drug-disease interactions.

Conclusions

The analysis of administrative claims data confirms the observations from clinical trials and further quantifies the incidence of warfarin drug-drug or drug-disease interactions associated with hemorrhage events. The frequency of concomitant warfarin use with metronidazole was 4.4% and with oral cephalosporins, 18.9%; 22.7% and 17.2%, respectively, of this concomitant use was associated with at least 1 hemorrhage event. There was no higher risk of a hemorrhage event for the concomitant use of warfarin with NSAIDs, including COX-2 inhibitors, amiodarone, or fibrin acid derivatives, compared with the use of warfarin alone, with absolute rates of hemorrhage in the range of 13.1% to 14.8% for these 3 drug-drug combinations versus a 14.2% prevalence of hemorrhage for use of warfarin alone. Patients diagnosed with liver disease or HF are more likely to experience a hemorrhage event while on warfarin therapy.

DISCLOSURES

No outside funding supported this research. Author Kui Zhang served as principal author of the study. Study concept and design were contributed by Zhang. Data collection was the work of Zhang and author Christopher Young; data interpretation was primarily the work of Zhang and Young, with input from author Jan Berger. Writing of the manuscript was primarily the work of Young, with input from Zhang, its revision was primarily the work of Young, with major input from Berger and input from Zhang. The authors disclose no potential bias or conflict of interest relating to this article.

REFERENCES


